The Florida Senate
BILL ANALYSIS AND FISCAL IMPACT STATEMENT
(This document is based on the provisions contained in the legislation as of the latest date listed below.)
Prepared By: The Professional Staff of the Committee on Health Policy
BILL: SB 1232
INTRODUCER: Senator Brodeur
SUBJECT: Telehealth Prescribing
DATE: March 24, 2023 REVISED:
ANALYST STAFF DIRECTOR REFERENCE ACTION
1. Stovall Brown HP Favorable
2. JU
3. RC
I. Summary:
SB 1232 authorizes a controlled substance listed in Schedule II of s. 893.03, F.S., to be
prescribed via telehealth by a telehealth provider for the treatment of a terminal condition or for
the treatment of cancer.
The bill provides an effective date of July 1, 2023.
II. Present Situation:
Telehealth
Section 456.47, F.S., defines the term “telehealth” as the use of synchronous or asynchronous
telecommunications technology by a telehealth provider to provide health care services,
including, but not limited to, assessment, diagnosis, consultation, treatment, and monitoring of a
patient; transfer of medical data; patient and professional health-related education; public health
services; and health administration. The term does not include audio-only telephone calls, e-mail
messages, or facsimile transmissions.1
In a general sense, “synchronous” telehealth happens in live, real-time settings where the patient
interacts with a provider, usually via phone or video. Providers and patients communicate
directly, often resulting in a diagnosis, treatment plan, or prescription. Synchronous telehealth
can include additional at-home devices such as a blood pressure or heart rate monitors,
thermometers, oximeters, cameras, or scales to help the provider more accurately assess the
patient’s health status.2
1
Section 456.47(1)(a), F.S.
2
TELEHEALTH.HHS.GOV, Synchronous direct-to-consumer telehealth, https://telehealth.hhs.gov/providers/direct-to-
consumer/synchronous-direct-to-consumer-telehealth/ (last visited Mar. 2, 2023).
BILL: SB 1232 Page 2
“Asynchronous” telehealth, also known as “store-and-forward,” is often used for patient intake
or follow-up care. For example, a patient sends a photo of a skin condition that is later reviewed
by a dermatologist who recommends treatment.3
Section 456.47, F.S., also authorizes out-of-state health care providers to use telehealth to deliver
health care services to Florida patients if they register with the applicable board,4 or the
Department of Health (DOH) if there is no board, and meet certain eligibility requirements.5 A
registered out-of-state telehealth provider may use telehealth, within the relevant scope of
practice established by Florida law and rule, to provide health care services to Florida patients,
but such providers are prohibited from opening an office in Florida, and from providing in-
person health care services to patients located in Florida, without first becoming licensed by the
state.6
A telehealth provider must document in the patient’s medical record the health care services
rendered using telehealth according to the same standard as used for in-person services. Medical
records, including video, audio, electronic, or other records generated as a result of providing
such services, are confidential.7
The website of an out-of-state telehealth provider registered under s. 456.47, F.S., must
prominently display a hyperlink to the DOH website, and the DOH website must publish a list of
all out-of-state registrants and include the following information for each:
Name.
Health care occupation.
Health care training and education, including completion dates and any certificates or
degrees obtained.
Out-of-state health care licenses, including license numbers.
Florida telehealth provider registration number.
Specialty, if any.
Board certification, if any.
Five years of disciplinary history, including sanctions imposed and board actions.
Medical malpractice insurance provider and policy limits, including whether the policy
covers claims that arise in Florida.
The name and address of the registered agent designated for service of process in Florida.8
A health care professional may not register under s. 456.47, F.S., if his or her license to provide
health care services is subject to a pending disciplinary investigation or action, or has been
revoked in any state or jurisdiction. A registered health care professional must notify the
appropriate board, or the DOH if there is no board, of any restrictions placed on his or her license
3
TELEHEALTH.HHS.GOV, Asynchronous direct-to-consumer telehealth, https://telehealth.hhs.gov/providers/direct-to-
consumer/asynchronous-direct-to-consumer-telehealth/ (last visited Mar. 2, 2023).
4
Under s. 456.001(1), F.S., the term “board” is defined as any board, commission, or other statutorily created entity, to the
extent such entity is authorized to exercise regulatory or rulemaking functions within the DOH or, in some cases, within the
DOH’s Division of Medical Quality Assurance (MQA).
5
See generally s. 456.47(4), F.S.
6
See s. 456.47(4)(f), F.S.
7
Section 456.47(3), F.S. (referencing ss. 395.3025(4) and 456.057, F.S., in connection with confidentiality).
8
Section 456.47(4)(c) and (4)(h), F.S.
BILL: SB 1232 Page 3
to practice, or any disciplinary action taken or pending against him or her, in any state or
jurisdiction. This notification must be provided within five business days after the restriction is
placed or the disciplinary action is initiated or taken.9
The board, or the DOH if there is no board, may take disciplinary action against an out-of-state
telehealth provider registered under s. 456.47, F.S., if the registrant:
Fails to notify the applicable board, or the DOH if there is no board, of any adverse action
taken against his or her license;
Has restrictions placed on, or disciplinary action taken against, his or her license in any state
or jurisdiction;
Violates any of the requirements of s. 456.47, F.S.; or
Commits any act that constitutes grounds for disciplinary action for Florida-licensed
providers.10
Disciplinary action taken by the applicable board, or the DOH if there is no board, may include
suspension or revocation of the provider’s registration, or the issuance of a reprimand or letter of
concern. A suspension may be accompanied by a corrective action plan as determined by the
board, or the DOH if there is no board, the completion of which may lead to the suspended
registration being reinstated according to rules adopted by the board, or the DOH if there is no
board.11
Venue for civil or administrative actions initiated by the DOH, the appropriate board, or a patient
who receives telehealth services from an out-of-state telehealth provider may be located in the
patient’s county of residence or in Leon County.12
A health care professional who is not licensed to provide health care services in Florida, but who
holds an active license to provide health care services in another state or jurisdiction, and who
provides such services using telehealth to a patient located in Florida, is not subject to the
registration requirement under s. 456.47, F.S., if the services are provided:
In response to an emergency medical condition; or
In consultation with a health care professional licensed in Florida who has ultimate authority
over the diagnosis and care of the patient.13
Controlled Substances
Chapter 893, F.S., sets forth the Florida Comprehensive Drug Abuse Prevention and Control Act.
This chapter classifies controlled substances into five schedules in order to regulate the
manufacture, distribution, preparation, and dispensing of the substances. The scheduling of
substances in Florida law is generally consistent with the federal scheduling of substances under
21 U.S.C. s. 812:
9
Section 456.47 (4)(d), F.S.
10
Section 456.47(4)(i), F.S. (referencing s. 456.072(1), F.S, or the applicable practice act, as the grounds for disciplinary
action).
11
Id.
12
Section 456.47(5), F.S.
13
Section 456.47(6), F.S. (referencing s. 395.002, F.S., in connection with emergency medical conditions).
BILL: SB 1232 Page 4
A Schedule I substance has a high potential for abuse and no currently accepted medical use
in treatment in the United States and its use under medical supervision does not meet
accepted safety standards. Examples include heroin and lysergic acid diethylamide (LSD).
A Schedule II substance has a high potential for abuse, a currently accepted but severely
restricted medical use in treatment in the United States, and abuse may lead to severe
psychological or physical dependence. Examples include cocaine and morphine.
A Schedule III substance has a potential for abuse less than the substances contained in
Schedules I and II, a currently accepted medical use in treatment in the United States, and
abuse may lead to moderate or low physical dependence or high psychological dependence
or, in the case of anabolic steroids, may lead to physical damage. Examples include lysergic
acid; ketamine; and some anabolic steroids.
A Schedule IV substance has a low potential for abuse relative to the substances in Schedule
III, a currently accepted medical use in treatment in the United States, and abuse may lead to
limited physical or psychological dependence relative to the substances in Schedule III.
Examples include alprazolam, diazepam, and phenobarbital.
A Schedule V substance has a low potential for abuse relative to the substances in Schedule
IV, a currently accepted medical use in treatment in the United States, and abuse may lead to
limited physical or psychological dependence relative to the substances in Schedule IV.
Examples include low dosage levels of codeine, certain stimulants, and certain narcotic
compounds.
The prescribing of controlled substances in Florida is regulated under s. 456.44, F.S. and the
various practice acts and board rules. Practitioners in Florida who are authorized to prescribe
controlled substances within their scope of practice include allopathic physicians ch. 458, F.S.,
osteopathic physicians ch. 459, F.S., podiatrists ch. 461, F.S., dentists ch. 466, F.S., physician
assistants licensed under ch. 458 or ch. 459, F.S., and advanced practice registered nurses
licensed under part I, ch. 464, F.S.
Controlled substance prescribing is more tightly regulated under s. 456.44, F.S., for the treatment
of acute pain and chronic nonmalignant pain, primarily due to the higher potential for substance
abuse and addiction. Under this section:
“Acute pain” is defined as the normal, predicted, physiological, and time-limited response to
an adverse chemical, thermal, or mechanical stimulus associated with surgery, trauma, or
acute illness. The term does not include pain related to cancer, a terminal condition,
palliative care to provide relief of symptoms related to an incurable, progressive illness or
injury, or a traumatic injury with an Injury Severity Score of 9 or greater.
“Chronic nonmalignant pain” is defined as pain unrelated to cancer which persists beyond
the usual course of disease or the injury that is the cause of pain or more than 90 days after
surgery.
Evolution of Telehealth Prescribing of Controlled Substances
When the authorization for health care practitioners to practice through telehealth was initially
enacted in 2019,14 telehealth providers were prohibited from prescribing any controlled
substance unless the controlled substance was prescribed for:
14
Chapter 2019-137, Laws of Fla.
BILL: SB 1232 Page 5
The treatment of a psychiatric disorder;
Inpatient treatment at a licensed hospital;
The treatment of a patient receiving hospice services; or
The treatment of a resident of a nursing home facility.
In 2022,15 this prohibition against prescribing any controlled substance unless it was for one of
the four exceptions was relaxed. Under current law, the restriction applies only to Schedule II16
drugs, so that a telehealth provider may not use telehealth to prescribe a controlled substance
listed in Schedule II of the state law establishing standards and schedules for controlled
substances17 unless the controlled substance is prescribed for the following:
The treatment of a psychiatric disorder;
Inpatient treatment at a licensed hospital;
The treatment of a patient receiving hospice services;18 or
The treatment of a resident of a nursing home facility.19, 20
III. Effect of Proposed Changes:
SB 1232 expands the conditions under which a telehealth provider may use telehealth to
prescribe a controlled substance listed in Schedule II to include the treatment of a terminal
condition as defined in s. 456.44(1)(2)2, F.S., or the treatment of cancer.
A terminal condition is defined in s. 456.44(1)(2)2, F.S., as a progressive disease or medical or
surgical condition that causes significant functional impairment, is not considered by a treating
physician to be reversible without the administration of life-sustaining procedures, and will result
in death within one year after diagnosis if the condition runs its normal course.
The bill provides an effective date of July 1, 2023.
IV. Constitutional Issues:
A. Municipality/County Mandates Restrictions:
None.
15
Chapter 2022-22, Laws of Fla.
16
Schedule II drugs, substances, or chemicals are defined as drugs with a high potential for abuse, with use potentially
leading to severe psychological or physical dependence. These drugs are also considered dangerous. Some examples of
Schedule II drugs are: combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), cocaine,
methamphetamine, methadone, hydromorphone (Dilaudid), meperidine (Demerol), oxycodone (OxyContin), fentanyl,
Dexedrine, Adderall, and Ritalin. U.S. Drug Enforcement Administration, Drug Scheduling, https://www.dea.gov/drug-
information/drug-scheduling (last visited Mar. 2, 2023).
17
Section 893.03, F.S.
18
Section 400.601(14). F.S., defines “hospice services” as items and services furnished to a patient and family by a hospice,
or by others under arrangements with such a program, in a place of temporary or permanent residence used as the patient’s
home for the purpose of maintaining the patient at home; or, if the patient needs short-term institutionalization, the services
must be furnished in cooperation with those contracted institutions or in the hospice inpatient facility.
19
Section 400.021(12), F.S, defines a “nursing home facility” as any facility which provides nursing services defined and
licensed under ch. 464 part I, F.S..
20
Section 456.47(2)(c), F.S.
BILL: SB 1232 Page 6
B. Public Records/Open Meetings Issues:
None.
C. Trust Funds Restrictions:
None.
D. State Tax or Fee Increases:
None.
E. Other Constitutional Issues:
None.
V. Fiscal Impact Statement:
A. Tax/Fee Issues:
None.
B. Private Sector Impact:
None.
C. Government Sector Impact:
None.
VI. Technical Deficiencies:
None.
VII. Related Issues:
None.
VIII. Statutes Affected:
This bill substantially amends section 456.47 of the Florida Statutes.
IX. Additional Information:
A. Committee Substitute – Statement of Changes:
(Summarizing differences between the Committee Substitute and the prior version of the bill.)
None.
BILL: SB 1232 Page 7
B. Amendments:
None.
This Senate Bill Analysis does not reflect the inte